How VSL#3® Provides Probiotic Support In Ulcerative Colitis (UC)

VSL#3® contains 8 diverse probiotic strains, each with a distinct mechanism to address barrier dysfunction among patients with mild-to-moderate UC1-5

*Reclassified as L. helveticus.
Reclassified as B. lactis.

At a Glance: See How VSL#3® Works

VSL#3® probiotic strains

A meta-analysis of 23 randomized controlled trials with a total of 1763 participants suggested probiotics containing a combination of multiple strains help preserve the mucosal barrier better than single-strain versions.11

The consensus document from the 4th Triennial Yale/Harvard Workshop on Probiotics recommended VSL#3®.12

VSL#3® for the Dietary Management of pouchitis

In clinical studies, VSL#3® is demonstrated to have a positive impact in patients with pouchitis.13,14

VSL#3® is recommended for the dietary management of pouchitis in the British Society for Gastroenterology Guidelines for the Management of Inflammatory Bowel Disease in Adults (2011) and the World Gastroenterology Organisation Global Guidelines for Inflammatory Bowel Disease (2015).15,16

For more information about VSL#3® for pouchitis, request a visit from your VSL#3® specialty sales representative.

Learn more about the safety profile of VSL#3®.

Safety in UC

References: 1. Cornick S, Tawiah A, Chadee K. Tissue Barriers. 2015;3(1-2):e982426. 2. Dai C, Zhao DH, Jiang M. Int J Mol Med. 2012;29(2):202-208. 3. Fedorak RN. J Clin Gastroenterol. 2008;42(suppl 3 [pt 1]):S111-S115. 4. Caballero-Franco C, Keller K, De Simone C, Chadee K. Am J Physiol Gastrointest Liver Physiol. 2007;292(1):G315-G322. 5. Lammers KM, Brigidi P, Vitali B, et al. FEMS Immunol Med Microbiol. 2003;38(2):165-172. 6. VSL#3® Product Information. Alfasigma USA, Covington, LA. 2017. 7. Brigidi P, Vitali B, Swennen E, Bazzocchi G, Matteuzzi D. Res Microbiol. 2001;152(8):735-741. 8. Biblioni R, Fedorak RN, Tannock GW, et al. Am J Gastroenterol. 2005;100(7):1539-1546. 9. Kumar S, Shukla R, Ranjan P, Kumar A. Clin Ther. 2017;39(3):632-643. 10. Hart AL, Lammers K, Brigidi P, et al. Gut. 2004;53(11):1602-1609. 11. Shen J, Zuo Z-X, Mao A-P. Inflamm Bowel Dis. 2014;20(1):21-35. 12. Floch MH, Walker WA, Sanders ME, et al. J Clin Gastroenterol. 2015;49(suppl 1):S69-S73. 13. Mimura T, Rizzello F, Helwig U, et al. Gut. 2004;53(1):108-114. 14. Gionchetti P, Rizzello F, Venturi A, et al. Gastroenterology. 2000;119(2):305-309. 15. Mowat C, Cole A, Windsor A, et al. Gut. 2011;60(5):571-607. 16. Bernstein CN, Eliakim A, Fedail S, et al. J Clin Gastroenterol. 2016;50(10):803-818.

*Reclassified as L. helveticus.
Reclassified as B. lactis.

References: 1. VSL#3 Product Information Sheet. 2017. 2. Bermudez-Brito M, Plaza-Díaz J, Muñoz-Quezada S, Gómez-Llorente C, Gil A. Ann Nutr Metab. 2012;61(2):160-174. 3. Maxwell LVT, Miller MJ. Nutrients. 2011;3:613-636. 4. Hart AL, Lammers K, Brigidi P, et al. Gut. 2004;53(11):1602-1609. 5. Lammers KM, Brigidi P, Vitali B, et al. FEMS Immunol Med Microbiol. 2003;38(2):165-172. 6. Dai C, Zhao D-H, Jiang M. Int J Mol Med. 2012;29(2):202-208.